  |
 | Up a level |
Bondarenko, I. and Sezer, A. and Kilickap, S. and Gümüs, M. and Özgüroğlu, M. and Gogishvili, M. and He, X. and Gullo, G. and Rietschel, P. and Quek, R.G. (2022) Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation. Annals of Oncology, Vol.33 (Supp.2). S84-S85. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Cristofanilli, Massimo and Rugo, Hope S. and Im, Seock-Ah and Slamon, Dennis J. and Harbeck, Nadia and Bondarenko, Igor and Masuda, Norikazu and Colleoni, Marco and DeMichele, Angela and Loi, Sherene and Iwata, Hiroji and O’Leary, Ben and André, Fabrice and Loibl, Sibylle and Bananis, Eustratios and Liu, Yuan and Huang, Xin and Sindy Kim, Sindy Kim and Frean, Maria Jose Lechuga and Turner, Nicholas C. (2022) Overall Survival With Palbociclib And Fulvestrant in Women With HR+/HER2– ABC: Updated Exploratory Analyses of PALOMA-3, a Double-Blind, Phase 3 Randomized Study. Clinical Cancer Research, 28 (16). pp. 3433-3442. ISSN 1078-0432 (print), 1557-3265 ( online)
Cristofanilli, Massimo and Rugo, Hope S. and Im, Seock-Ah and Slamon, Dennis J. and Harbeck, Nadia and Bondarenko, Igor and Masuda, Norikazu and Colleoni, Marco and DeMichele, Angela and Loi, Sherene and Iwata, Hiroji and O’Leary, Ben and André, Fabrice and Loibl, Sibylle and Bananis, Eustratios and Yuan Liu, Yuan Liu and Huang, Xin and Kim, Sindy and Frean, Maria Jose Lechuga and Turner, Nicholas C. (2022) Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clinical Cancer Research, 28 (16). pp. 3433-3442. ISSN 1078-0432 (print), 1557-3265 ( online)
Li, R.K. and Tokunaga, E. and Adamchuk, H. and Vladimirov, V. and Yanez, E. and Lee, K.S. and Bondarenko, I. and Vana, A. and Hilton, F. and Ishikawa, T. and Tajima, K. and Lipatov, O. (2022) Long‑Term Safety and Efectiveness of PF‑05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2‑Positive Metastatic Breast cancer: Updated Results of a Randomized, Double‑Blind Study. BioDrugs, 36. pp. 55-69. ISSN 1173-8804 (Print) 1179-190X (Online)
Paz-Ares, L. and Chen, Y. and Reinmuth, N. and Hotta, K. and Trukhin, D. and Statsenko, G. and Hochmair, M. J. and Özgüroglu, M. and Ji, J.H. and Garassino, M. C. and Voitko, O. and Poltoratskiy, A. and Musso, E. and Havel, L. and Bondarenko, I. and Losonczy, G. and Conev, N. and Mann, H. and Dalvi, T. B. and Jiang, H. and Goldman, J. W. (2022) Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open, Vol. 7 (no. 2). p. 100408. ISSN 2059-7029 (Online)
Shah, M.A. and Udrea, A.A. and Bondarenko, I. and Mansoor, W. and Sánchez, R.G. and Sarosiek, T. and Bozzarelli, S. and Schenker, M. and Gomez-Martin, C. and Morgan, C. and Özgüroglu, M. and Pikiel, J. and Kalofonos, H.P. and Wojcik, E. and Buchler, T. and Swinson, D. and Cicin, I. and Joseph, M. and Vynnychenko, I. and Luft, A.V. and Enzinger, P.C. and Salek, T. and Papandreou, C. and Tournigand, C. and Maiello, E. and Wei, R. and Ferry, D. and Gao, L. and Oliveira, J.M. and Ajani, J.A. (2022) Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers, Vol.14 (iss. 5). p. 1168. ISSN 2072-6694
